Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 Fields, 2017, Hodgkin lymphoma, Medicine., 45, 305, 10.1016/j.mpmed.2017.02.003 Armitage, 2017, Non-hodgkin lymphoma, The Lancet., 390, 298, 10.1016/S0140-6736(16)32407-2 Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. Ku, 2017, Tumour cell surface antigen targeted therapies in B-cell lymphomas: beyond rituximab, J Blood Reviews., 31, 23, 10.1016/j.blre.2016.08.001 Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Wolska-Washer, 2017, Emerging antibody-drug conjugates for treating lymphoid malignancies, Expert Opin Emerging Drugs, 22, 259, 10.1080/14728214.2017.1366447 Thomas, 2016, Antibody–drug conjugates for cancer therapy, Lancet Oncol, 17, e254, 10.1016/S1470-2045(16)30030-4 Lopus, 2011, Antibody-DM1 conjugates as cancer therapeutics, Cancer Lett, 307, 113, 10.1016/j.canlet.2011.03.017 Drake, 2017, Recent developments in ADC technology: preclinical studies signal future clinical trends, BioDrugs., 31, 521, 10.1007/s40259-017-0254-1 Donaghy, 2016, Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates, MAbs., 8, 659, 10.1080/19420862.2016.1156829 Staudacher, 2017, Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?, Br J Cancer, 117, 1736, 10.1038/bjc.2017.367 Schirrmann, 2014, CD30 as a therapeutic target for lymphoma, BioDrugs., 28, 181, 10.1007/s40259-013-0068-8 Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236-43. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-42. Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735-42. Hoppe, 2018, NCCN guidelines insights: Hodgkin lymphoma, version 1.2018, J Natl Compr Canc Netw, 16, 245, 10.6004/jnccn.2018.0013 Evens, 2018, Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma, J Clin Oncol, 36, 3015, 10.1200/JCO.2018.79.0139 Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-94. Abramson JS, Redd RA, Barnes JA, Bengtson E, Takvorian RW, Sokol L, et al. A Phase II study of brentuximab vedotin plus Adriamycin and dacarbazine without radiation in non-bulky limited stage classical Hodgkin lymphoma. Blood. 2018;132(Supplement 1):1654-. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993. Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, et al. Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 2018;132(Supplement 1):928-. Collins, 2019, Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT-301, CAMI) in relapsed/refractory (r/r) classical hodgkin lymphoma (CHL), Hematol Oncol, 37, 95, 10.1002/hon.61_2629 Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394-402. Shah, 2015, Characterization of CD22 expression in acute lymphoblastic leukemia, Pediatric Blood Cancer., 62, 964, 10.1002/pbc.25410 Kantarjian, 2016, Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia, N Engl J Med, 375, 740, 10.1056/NEJMoa1509277 Fayad, 2013, Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab, J Clin Oncol, 31, 573, 10.1200/JCO.2012.42.7211 Pfeifer, 2015, Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes, Leukemia, 29, 1578, 10.1038/leu.2015.48 Palanca-Wessels, 2015, Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study, Lancet Oncol, 16, 704, 10.1016/S1470-2045(15)70128-2 Sehn, 2020, Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma, J Clin Oncol, 38, 155, 10.1200/JCO.19.00172 Morschhauser, 2019, Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), The Lancet Haematology., 6, e254, 10.1016/S2352-3026(19)30026-2 Wang, 2012, CD19: a biomarker for B cell development, lymphoma diagnosis and therapy, Experimental hematology & oncology., 1, 1, 10.1186/2162-3619-1-36 Jurczak, 2018, Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, Ann Oncol, 29, 1266, 10.1093/annonc/mdy056 Salles, 2020, Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study, Lancet Oncol, 21, 978, 10.1016/S1470-2045(20)30225-4 Kahl, 2017, First clinical results of ADCT-402, a novel pyrrolobenzodiazepine-based antibody drug conjugate (ADC), in relapsed/refractory B-cell lineage NHL, Hematol Oncol, 35, 49, 10.1002/hon.2437_33 Trnĕný, 2018, A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy, Haematologica, 103, 1351, 10.3324/haematol.2017.168401 Moskowitz CH, Fanale MA, Shah BD, Advani RH, Chen R, Kim S, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed/refactory B-lineage non-Hodgkin lymphoma. Blood. 2015. Chen RW, Jacobsen ED, Kostic A, Liu T, Moskowitz CH. A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT). Journal of Clinical Oncology. 2016. Schröder, 2016, The multifaceted roles of the invariant chain CD74—More than just a chaperone, Biochimica et Biophysica Acta-Molecular Cell Research., 1863, 1269, 10.1016/j.bbamcr.2016.03.026 Stein, 2007, CD74: a new candidate target for the immunotherapy of B-cell neoplasms, Clin Cancer Res, 13, 5556s, 10.1158/1078-0432.CCR-07-1167 Abrahams, 2018, Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001, Oncotarget., 9, 37700, 10.18632/oncotarget.26491 Shah, 2019, Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies, Blood, 10.1182/blood-2019-122754 Govindan, 2013, Milatuzumab–SN-38 conjugates for the treatment of CD74+ cancers, Mol Cancer Ther, 12, 968, 10.1158/1535-7163.MCT-12-1170 Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL. NCT01585688. Lapalombella, 2012, Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals, Cancer Cell, 21, 694, 10.1016/j.ccr.2012.03.040 Hicks, 2017, The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models, Neoplasia., 19, 661, 10.1016/j.neo.2017.06.001 Stathis, 2018, Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study, Invest New Drugs, 36, 869, 10.1007/s10637-018-0570-4 Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095-100. Horwitz, 2019, Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial, The Lancet., 393, 229, 10.1016/S0140-6736(18)32984-2 Prince, 2017, Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial, The Lancet., 390, 555, 10.1016/S0140-6736(17)31266-7 Horwitz, 2017130, Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL), Blood Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL). NCT01925612. Pro, 2012, Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study, J Clin Oncol, 30, 2190, 10.1200/JCO.2011.38.0402 LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-8. Tilly H, Sharman J, Bartlett N, Morschhauser F, Haioun C, Munoz J, et al. Pola‐R‐chp: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B‐cell lymphoma. Hematological Oncology. 2017;35:90-1. Diefenbach, 2019, Polatuzumab vedotin (Pola)+ obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial, J Clin Oncol, 10.1200/JCO.2019.37.15_suppl.7505 Topp, 2020, Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma, Haematologica, 105, e256, 10.3324/haematol.2019.233189 Goy, 2016, A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy, Br J Haematol, 174, 571, 10.1111/bjh.14094 Sangha, 2017, Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma, Journal of drug assessment., 6, 10, 10.1080/21556660.2017.1315336 Dang, 2018, Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, Br J Haematol, 182, 583, 10.1111/bjh.14820 Chung KY, Hamadani M, Kahl BS, Heffner LT, Caimi PF, Feingold JM, et al. A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). Journal of Clinical Oncology. 2016. Radford J, Kahl BS, Hamadani M, Carlo-Stella C, Caimi P, Ardeshna KM, et al. Interim results from the first-in-human clinical trial of Adct-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132(Supplement 1):398-. Carlo-Stella C, Zinzani PLL, Kahl BS, Caimi P, Solh M, Townsend W, et al. Interim futility analysis of a phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2019;134(Suppl 1):757. Horwitz, 2017, Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate in relapsed/refractory hodgkin/non-hodgkin lymphoma, Hematological Oncology, 35, 270, 10.1002/hon.2438_143